LMP Capital and Income Fund offers a 9.7% yield, focusing on income generation through a diversified asset mix, but has underperformed recently. SCD trades at an 8.68% discount to NAV, yet remains ...

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...

NICM: 6.10 appropriate treatments per 100 patient-years MI/CAD: 8.64 appropriate treatments per 100 patient-years The rate of appropriate LifeVest treatments in SCD-PROTECT was significantly higher ...

Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...

The Department of Health and Human Services (HHS), Office of Minority Health requests that the National Academies of Sciences, Engineering, and Medicine convene an ad hoc committee to develop a ...

Sickle cell disease is one of the most common inherited blood disorders worldwide, with a particularly heavy burden in sub-Saharan Africa. Every year, hundreds of thousands of infants are born with ...

India accounts for the second-highest prevalence of sickle cell disease (SCD) globally, following sub-Saharan Africa. However, not much research has been done, and no stigma measurement tool was ...

Vertex unveiled long-term durability data for Casgevy, while Beam presented Phase I/II findings for its investigational base editor BEAM-101, building up to a BLA by late 2026. In a presentation set ...

The global withdrawal of voxelotor (Oxbryta, Pfizer) has left clinicians who treat sickle cell disease (SCD) with the urgent task of reaching patients taking the medicine, while trying to understand ...

Sixteen patients dosed with Pfizer’s sickle cell disease drug Oxbryta® (voxelotor) in a pair of clinical trials have died, European regulators disclosed hours before Pfizer said it was voluntarily ...